we conclude that combination intraperitoneal therapy with cisplatin , cytosine arabinoside , and doxorubicin can be safely administered with objective tumor responses observed in patients with ovarian cancer heavily pretreated and in individuals with other malignancies involving the peritoneal cavity .
C0027651
tumor
C0006826
malignancies